Loading dashboard...
Peptide Assistant
Online
AI can make mistakes. Verify important medical data.
Press Enter to send
G
Medical Engine
Guest Account
AI can make mistakes. Verify important medical data.
Press Enter to send
Medical Engine
Guest Account
Loading dashboard...
Reprogramming aging at the genetic level. Turning back the epigenetic clock.
Aging is increasingly viewed as a programmable process. Certain genes (Klotho, TERT, FOXO3) are associated with exceptional longevity. Gene therapy could activate these protective pathways permanently, effectively slowing or reversing biological decay.
| Gene / Pathway | Function | Therapy Status | Potential Effect |
|---|---|---|---|
| Telomerase (TERT) | Extends telomeres | Animal trials / Self-experiment | 24% lifespan extension (mice) |
| Klotho | Anti-aging hormone | Early research | Cognitive & CV protection |
| FOXO3 | Stress resistance | Preclinical | Associated with Centenarians |
| Yamanaka Factors | Cellular reprogramming | Active (Altos Labs) | Epigenetic age reversal |
| Sirtuin Activators | Metabolic regulation | Molecules available | Healthspan extension |
The most exciting development in longevity. Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) can reprogram adult cells back to a stem-like state. Partial reprogramming—using these factors briefly—can reverse epigenetic age without losing cell identity.
More approved gene therapies for orphan diseases. Refinement of delivery systems (AAV/LNP).
First longevity-focused gene therapies (TERT, Klotho) enter early human safety trials.
Anti-aging gene therapies become elective options in optimization centers.
Note: Medical tourism centers in unregulated jurisdictions may offer earlier, high-risk access to these technologies.